Véronique Pomi-Schneiter Resigns from BioSenic
In a major shift in leadership, BioSenic (Euronext Brussels and Paris: BIOS), a company recognized for its commitment to developing solutions for serious autoimmune and inflammatory conditions, has announced that Véronique Pomi-Schneiter has resigned from her position as Deputy CEO. This decision allows her to focus on her health while continuing to lend her expertise as a non-executive board member.
Leadership Change and Ongoing Support
Prof. François Rieger, the CEO and Chairman of the Board at BioSenic, extended heartfelt wishes for Véronique's speedy recovery. He acknowledged her steadfast dedication and profound understanding of the company’s strategic direction. Prof. Rieger highlighted her continuing involvement, confirming that she will still oversee her responsibilities at Medsenic, a subsidiary of BioSenic, ensuring a smooth transition during this period.
BioSenic's Focus on Innovative Autoimmune Therapies
BioSenic is well-regarded for its pioneering research and development, particularly aimed at addressing autoimmune conditions. The company is at the forefront of utilizing the arsenic trioxide (ATO) platform developed by Medsenic to tackle urgent medical issues like graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), and the newly included systemic sclerosis (SSc).
The Effects of Mergers on BioSenic’s Strategy
Since merging with Bone Therapeutics in late 2022, BioSenic has solidified its ability to leverage the combined expertise of both organizations. This merger has improved BioSenic's drug development pipeline, which now features a wide range of anti-inflammatory and anti-autoimmune treatments that make use of the outstanding qualities of ATO and oral ATO (OATO).
Progress in the ATO Platform
The ATO platform is essential to BioSenic’s research efforts, significantly contributing to therapies aimed at managing chronic conditions. It plays a crucial role in onco-immunology, particularly for GvHD, a severe issue that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
BioSenic's dedication to advancing treatment options is demonstrated by its successful phase 2 trial of its intravenous formulation, Arscimed®. This formulation has garnered orphan drug designation from regulatory bodies such as the FDA and EMA, highlighting its potential to meet critical medical needs.
Looking Forward: Future Plans for BioSenic
The company is preparing for an international phase 3 confirmatory study involving its innovative OATO formulation, protected by intellectual property laws. BioSenic is also actively researching effective treatments for moderate-to-severe SLE, benefiting from the encouraging results observed in previous studies.
Systemic Sclerosis: Targeting a Challenging Condition
Systemic sclerosis, a chronic illness affecting the skin, lungs, and blood vessels, is increasingly becoming a focus in BioSenic's clinical development pipeline. Currently, there are no effective treatments available for this condition. However, preclinical studies conducted in relevant animal models have shown promising results, setting the stage for a potential phase 2 clinical protocol that utilizes new immunomodulatory formulations directed at this complex disease.
Commitment to Innovation and Research
BioSenic continues to prioritize its research and development endeavors across its autoimmune platforms. The company is also investigating innovative approaches in cell therapy for organ repair, using the unique properties of Mesenchymal Stromal Cells (MSCs) sourced from bone marrow.
Fostering Communication Amidst Change
During this transition period, BioSenic is committed to maintaining open lines of communication with its stakeholders. For inquiries or further details about the company’s direction or ongoing projects, individuals can directly contact BioSenic’s CEO, François Rieger, via email or phone.
Frequently Asked Questions
What was the reason for Véronique Pomi-Schneiter’s resignation?
Véronique stepped down to focus on her health but will continue to assist BioSenic as a non-executive board member.
How will the leadership change influence BioSenic's strategy?
This transition aims to ensure continuity in leadership and support BioSenic's ongoing initiatives, especially in developing treatments for autoimmune diseases.
What are BioSenic's main research focuses?
BioSenic’s primary research focuses on developing therapies for autoimmune diseases such as GvHD, SLE, and systemic sclerosis through its ATO platform.
What makes the Arscimed® formulation significant?
Arscimed® holds orphan drug designation, which underscores its potential to address critical gaps in treatment options for rare diseases.
What innovations is BioSenic pursuing in the field of cell therapy?
BioSenic is looking into new methodologies using Mesenchymal Stromal Cells for organ repair, reflecting its ongoing commitment to advancing cutting-edge research in cell therapy.
